Peter J Hoskin1,2, Kirsten Hopkins3, Vivek Misra4, Tanya Holt5, Rhona McMenemin6, Danny Dubois7, Fiona McKinna8, Bernadette Foran9, Krishnaswamy Madhavan10, Carol MacGregor11, Andrew Bates12, Noelle O'Rourke13, Jason F Lester14, Tim Sevitt15, Daniel Roos16,17, Sanjay Dixit18, Gillian Brown9, Seonaid Arnott11, Sharon Shibu Thomas10, Sharon Forsyth19, Sandy Beare19, Krystyna Reczko19, Allan Hackshaw19, Andre Lopes19. 1. Mount Vernon Cancer Centre, Northwood, United Kingdom. 2. University of Manchester, Manchester, United Kingdom. 3. Bristol Centre for Haematology and Oncology Bristol, Bristol, United Kingdom. 4. The Christie Hospital, Manchester, United Kingdom. 5. Princess Alexandra Hospital, University of Queensland, Brisbane, Australia. 6. The Freeman Hospital, Newcastle, United Kingdom. 7. Queen Alexandra Hospital, Portsmouth, United Kingdom. 8. Royal Sussex County Hospital, Brighton, United Kingdom. 9. Weston Park Hospital, Sheffield, United Kingdom. 10. Southend University Hospital, United Kingdom. 11. Raigmore Hospital, Inverness, United Kingdom. 12. Southampton General Hospital, Southampton, United Kingdom. 13. The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. 14. Velindre Cancer Centre, Cardiff, United Kingdom. 15. Kent Oncology Centre, Maidstone, United Kingdom. 16. Royal Adelaide Hospital, Adelaide, Australia. 17. University of Adelaide, Adelaide, Australia. 18. Castle Hill Hospital, Hull, United Kingdom. 19. CRUK & UCL Cancer Trials Centre, London, United Kingdom.
Abstract
Importance: Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. Objective: To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy. Design, Setting, and Participants: Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017. Interventions: Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341). Main Outcomes and Measures: The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival. Results: Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to ∞]; P value for noninferiority = .004) at week 1, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion. Conclusions and Relevance: Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding. Trial Registration: ISRCTN Identifiers: ISRCTN97555949 and ISRCTN97108008.
RCT Entities:
Importance: Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. Objective: To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy. Design, Setting, and Participants: Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017. Interventions: Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341). Main Outcomes and Measures: The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival. Results: Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to ∞]; P value for noninferiority = .004) at week 1, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion. Conclusions and Relevance: Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding. Trial Registration: ISRCTN Identifiers: ISRCTN97555949 and ISRCTN97108008.
Authors: Kim Cocks; Madeleine T King; Galina Velikova; Marrissa Martyn St-James; Peter M Fayers; Julia M Brown Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Yolande Lievens; Noémie Defourny; Mary Coffey; Josep M Borras; Peter Dunscombe; Ben Slotman; Julian Malicki; Marta Bogusz; Chiara Gasparotto; Cai Grau; Arianit Kokobobo; Felix Sedlmayer; Elena Slobina; Philippe Coucke; Roumen Gabrovski; Milan Vosmik; Jesper Grau Eriksen; Jana Jaal; Catherine Dejean; Csaba Polgar; Jakob Johannsson; Moya Cunningham; Vydmantas Atkocius; Carlo Back; Martin Pirotta; Vanja Karadjinovic; Sverre Levernes; Boguslaw Maciejewski; Maria Lurdes Trigo; Barbara Šegedin; Amalia Palacios; Bert Pastoors; Charlotte Beardmore; Sara Erridge; Gaile Smyth; Ramon Cleries Soler Journal: Radiother Oncol Date: 2014-11-12 Impact factor: 6.280
Authors: Chun Chieh Lin; Suanna S Bruinooge; M Kelsey Kirkwood; Dawn L Hershman; Ahmedin Jemal; B Ashleigh Guadagnolo; James B Yu; Shane Hopkins; Michael Goldstein; Dean Bajorin; Sharon H Giordano; Michael Kosty; Anna Arnone; Amy Hanley; Stephanie Stevens; Christine Olsen Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-17 Impact factor: 7.038
Authors: K A Lee; M Dunne; C Small; P J Kelly; O McArdle; J O'Sullivan; D Hacking; M Pomeroy; J Armstrong; M Moriarty; A Clayton-Lea; I Parker; C D Collins; P Thirion Journal: Acta Oncol Date: 2018-02-08 Impact factor: 4.089
Authors: Rachel McDonald; Keyue Ding; Michael Brundage; Ralph M Meyer; Abdenour Nabid; Pierre Chabot; Genevieve Coulombe; Shahida Ahmed; Joda Kuk; A Rashid Dar; Aamer Mahmud; Alysa Fairchild; Carolyn F Wilson; Jackson S Y Wu; Kristopher Dennis; Carlo DeAngelis; Rebecca K S Wong; Liting Zhu; Stephanie Chan; Edward Chow Journal: JAMA Oncol Date: 2017-07-01 Impact factor: 31.777
Authors: Julio C Furlan; Jefferson R Wilson; Eric M Massicotte; Arjun Sahgal; Michael G Fehlings Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 13.029
Authors: Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed Journal: Clin Transl Radiat Oncol Date: 2020-03-24
Authors: Divya Yerramilli; Amy J Xu; Erin F Gillespie; Annemarie F Shepherd; Kathryn Beal; Daniel Gomez; Josh Yamada; C Jillian Tsai; T Jonathan Yang Journal: Adv Radiat Oncol Date: 2020-04-08
Authors: Jie Jane Chen; Adam J Sullivan; Diana D Shi; Monica S Krishnan; Lauren M Hertan; Claudia S Roldan; Mai Anh Huynh; Alexander Spektor; M Mohsin Fareed; Tai Chung Lam; Tracy A Balboni Journal: Adv Radiat Oncol Date: 2021-02-07